At a glance
About the study
The purpose of this research study is to investigate the safety, tolerability and activity of the investigational drug Laquinimod in patients with Huntington’s Disease (HD) at different concentrations (0.5, 1.0, 1.5mg/day).
Laquinimod was developed as an anti-inflammatory drug, to dampen the activity of the body’s immune system, for treatment of diseases such as Multiple Sclerosis, Lupus and Crohn’s Disease. Laquinimod has already been tested for safety and effectiveness in these diseases.
The immune system has been found to be hyperactive in HD and research in animal models of the disease suggests that reducing this hyperactivity may help to improve signs and symptoms of the disease and slow progression. This is a small international trial to investigate the safety of the drug in HD patients and to look for potential beneficial effects of Laquinimod, at different doses, on patient symptoms.
What is involved?
The drug is taken orally every day for 12 months. The study will last a total of 14 months including a 2-5 week observational period followed by 12 months of treatment and a four week follow up period, after the last treatment.
Patients will attend the study centre approximately 8 times throughout the study for assessments including cognitive tests and questionnaires. Patients will also provide blood and urine samples for analysis and undergo two MRI scans, one at the beginning of treatment and one at the end. Study visits may last all day and refreshments will be provided along with reimbursement of travel costs.
Who can take part?
This study is recruiting approximately 65 patients with HD, between the ages of 21-55. Participants must be willing and able to take daily oral medication and travel to the study centre for full day assessments approximately 8 times throughout the trial. Participants will need to attend with a caregiver who will be asked to provide information during the trial about their HD symptoms and care.
Please contact the HD research team on 0203 108 7483 for more information.